

*Liver fibrosis was induced by IP administration of thioacetamide (TAA) at a dose of 250 mg/kg twice weekly for 8 weeks in male Wistar rats (10-12 weeks of age). Rats (n=10/group) received either vehicle control, or CM-101 2.5mg/kg IV twice weekly during weeks 4-8 (following established fibrosis) and were sacrificed at Week 8.

Methods

TAA

Overall Study Design

TAA +CM-101

(2.5mg/kg)

nificantly reduced liver collagen in rat model with established liver fibrosis

This was a single country, multi-center, double-blinded, randomized, placebo-controlled trial in patients with non-cirrhotic NASH and biopsy-confirmed F1c-F3 fibrosis

	Total Study Duration 20 weeks			
6-Week Screening	14-Week (8 administrations) Double-blind Treatment Period	6-week Follo up		
N =23 patients 2:1 (Active vs. Placebo)	CM-101 5mg/kg SQ Q2W (n=14)*	Post-dosin		
	Placebo SQ Q2W (n=9)*	safety follow		
*Intention to treat popula	ition			

intention to treat population

Study Endpoints

Primary Endpoint:

• Safety and tolerability of CM-101 in subjects with NASH as assessed by adverse events and serious adverse events

- **Selected Secondary Endpoints:** CM-101 Serum PK profile
- Development of anti-drug antibodies (ADA)
- Change from baseline in serum biomarkers for NASH pathogenesis, inflammatory, fibrotic and pharmacodynamic parameters
- Change from baseline in liver stiffness

References

Mor A, et al. Ann Rheum Dis. 2019;78:1260. Segal-Salto M, et al. JHEP Rep. 2020;2:100064. Taru M-G, et al. Diagnostics. 2023; 13:788.

Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: A proof-of-concept study

Rifaat Safadi¹, John Lawler², Revital Aricha², Ilan Vaknin², Scott Friedman³, Adi Mor² ¹Hadassah Hebrew University Hospital, Israel, ²Chemomab Therapeutics, Ltd, United States, ³Icahm School of Medicine, United States

Methods

Histological confirmation of steatohepatitis and fibrosis without cirrhosis on a diagnostic liver biopsy obtained within the 18 months prior to randomization with a NAS score \geq 4 with a score of at least 1 for

• Male or Female; Age 18-75 years

Key Inclusion Criteria

- each component (steatosis, ballooning degeneration and lobular inflammation), and with hepatic fibrosis stage 1C, 2 or 3 as defined by the NASH CRN scoring scale
- Presence of ≥ 10% steatosis on MRI-derived protondensity fat-fraction (PDFF)
- Confirmation of disease status from time of biopsy by Transient Elastography with liver stiffness value of 7-12 kPa
- Body mass index between 25-45 kg/m²

Key Exclusion Criteria

- History or presence of cirrhosis (compensated or decompensated) determined by histology or relevant medical complications and laboratory parameters
- Evidence of drug induced steatohepatitis secondary to medications known to cause hepatic steatosis Model for End-stage Liver Disease (MELD) score >12
- History of liver transplant, or current evaluation for or placement on a liver transplant waiting list
- History or evidence of any of the following: Alcoholic liver disease, Hepatitis B, Hepatitis A, autoimmune hepatitis, PBC, PSC, Wilson's Disease, alpha-1-antitrypsin deficiency, hemochromatosis, drug-induced liver disease, malignancy

Baseline Characteristics

Results

	CM-101 (N=14)*	Placebo (N=9)*		CM-101 (N=14)*
Demographics			Liver Disease Severity	
Age (Years)	53.8 (11.4)	46.6 (16.8)	Fibrosis Stage 1a	0 (0%)
Female gender (%)	6 (42.9%)	6 (66.7%)	Fibrosis Stage 1c	6 (42.9%)
White (%)	14 (100%)	9 (100%)	Fibrosis Stage 2	3 (21.4%)
Liver Enzymes			Fibrosis Stage 3	5 (35.7%)
Alanine Aminotransferase (U/L)	33.8 (13.0)	29.5 (6.5)	MELD Score	7.7 (2.6)
Aspartate Aminotransferase (U/L)	45.8 (25.8)	45.6 (23.1)	Liver Imaging	
Lipids			**Liver Stiffness [*] E(kPa)	11.5 (5.2)
Triglycerides – mg/dL	142.8 (52.1)	157.6 (67.9)	***Liver fat percentage (%)	19.0 (7.0)
LDL-Cholesterol – mg/dL	93.2 (30.5)	112.1 (32.7)	Biomarkers	
Type 2 Diabetes Mellitus	10 (76.9%)	3 (33.3%)	ELF score	9.8 (0.9)
NAFLD Activity Score (NAS)	4.6 (1.5)	4.8 (0.8)	Pro-C3 (ng/mL)	40.0 (8.9)
FAST Score	0.53 (0.23)	0.34 (0.19)	Fibrosis-4 (FIB4) score	1.5 (1.2)
ata presented as n (%) or mean (SD) unl	ess otherwise st	ated	C-reactive protein (CRP) (mg/dL)	1.2 (1.0)
AFLD = Nonalcoholic fatty liver disease; Analysis was per protocol population (CM	Serum CCL24 (pg/ml)	1101 (852)		
LF = Enhanced Liver Fibrosis By VCTE, FibroScan; *** by MRI-PDFF		,	Neutrophil – Lymphocyte Ratio (NLR)	2.29 (0.86)

Data presented as n (%) or mean (SD) unless otherwise stated NAFLD = Nonalcoholic fatty liver disease; FAST = FibroScan-AST * Analysis was per protocol population (CM-101 n=13, Placebo n = 8) ELF = Enhanced Liver Fibrosis

Safety and Tolerability

- CM-101 5mg/kg SQ every 2 weeks for 14
- weeks was safe and well tolerated Most adverse events (AEs) were mild with
- one unrelated serious adverse event.
- No ADAs were detected at 20 weeks.


Adverse Events	CM-101 (N=14)	Placebo (N=9)
Any TEAEs*	10 (71.4%)	8 (88.5%)
Any Related TEAEs	5 (35.7%)	6 (66.7%)
Any SAEs	1 (7.1%)	0 (0%)
Any Related SAEs	0 (0%)	0 (0%)


*TEAEs- Treatment emergent adverse events; **SAEs –Serious adverse events


Injection site erythema and injection site pruritis were the most frequently reported TEAEs in the CM-101 group 21.9% and 6.3%, respectively compared to placebo 0% and 0%, respectively.


Target Engagement

CM-101 demonstrated a favorable **PK-target engagement profile**











Changes in FIB-4 Score

Effects on Fibrosis Biomarkers **CM-101** was associated with improvements in multiple fibrosis markers





High CCL24 defined as >610 pg/mL; Low CCL24 defined as <610 pg/mL

Conclusions

- CM-101 (5mg/kg) administered SQ every 2 weeks for 14 weeks was safe and well tolerated.
- CM-101 demonstrated a favorable PK-target engagement profile
- CM-101 was associated with improvements in multiple fibrosis markers
- CM-101 was associated with a reduction in liver stiffness stage, FIB-4 Score, and AST/ALT Ratio • Neutralizing the pro-inflammatory and pro-fibrotic effects of CCL24 with CM-101 at higher doses and for
- a prolonged duration merits further study
- Results from this study provided evidence supporting CCL24 as a potential therapeutic target in NASH.

Results

